| __timestamp | Neurocrine Biosciences, Inc. | Pfizer Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 46425000 | 8393000000 |
| Thursday, January 1, 2015 | 81491000 | 7690000000 |
| Friday, January 1, 2016 | 94291000 | 7872000000 |
| Sunday, January 1, 2017 | 121827000 | 7657000000 |
| Monday, January 1, 2018 | 160524000 | 8006000000 |
| Tuesday, January 1, 2019 | 200000000 | 8650000000 |
| Wednesday, January 1, 2020 | 275000000 | 9405000000 |
| Friday, January 1, 2021 | 328100000 | 13829000000 |
| Saturday, January 1, 2022 | 463800000 | 11428000000 |
| Sunday, January 1, 2023 | 565000000 | 10679000000 |
| Monday, January 1, 2024 | 731100000 | 10930000000 |
Unleashing insights
In the ever-evolving landscape of pharmaceuticals, research and development (R&D) expenses are a critical indicator of a company's commitment to innovation. Over the past decade, Pfizer Inc. and Neurocrine Biosciences, Inc. have demonstrated contrasting yet intriguing R&D investment strategies. From 2014 to 2023, Pfizer's R&D expenses have consistently dwarfed those of Neurocrine, with Pfizer investing nearly 40 times more on average. However, Neurocrine's R&D spending has shown a remarkable growth trajectory, increasing by over 1,100% from 2014 to 2023. This surge reflects Neurocrine's aggressive push towards expanding its research capabilities. Meanwhile, Pfizer's R&D expenses peaked in 2021, coinciding with the global demand for innovative healthcare solutions. These trends underscore the dynamic nature of R&D investments and their pivotal role in shaping the future of healthcare.
Who Prioritizes Innovation? R&D Spending Compared for AbbVie Inc. and Neurocrine Biosciences, Inc.
Pfizer Inc. or Amgen Inc.: Who Invests More in Innovation?
Research and Development Expenses Breakdown: Pfizer Inc. vs Alnylam Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Pfizer Inc. vs Ascendis Pharma A/S
Analyzing R&D Budgets: Pfizer Inc. vs CRISPR Therapeutics AG
Research and Development Investment: Gilead Sciences, Inc. vs Neurocrine Biosciences, Inc.
R&D Insights: How Neurocrine Biosciences, Inc. and BioMarin Pharmaceutical Inc. Allocate Funds
R&D Spending Showdown: Neurocrine Biosciences, Inc. vs Pharming Group N.V.
Neurocrine Biosciences, Inc. or CymaBay Therapeutics, Inc.: Who Invests More in Innovation?
Research and Development Expenses Breakdown: Neurocrine Biosciences, Inc. vs Amicus Therapeutics, Inc.
Neurocrine Biosciences, Inc. vs ACADIA Pharmaceuticals Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Soleno Therapeutics, Inc.